Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „acalabrutinib“
Suchtreffer
Begriffe & Kennungen
Calquence · 4.5 · 47 inhibitors, H2-receptor antagonists, antacids), unlike acalabrutinib capsules which show impaired uptake wh
Eintrag öffnenCalquence · 4.5 · Acalabrutinib and its active metabolite are primarily metabolised by cytochrome P450 enzyme 3A4 (CYP3A4), and
Eintrag öffnenCalquence · 4.5 · Acalabrutinib and its active metabolite are primarily metabolised by cytochrome P450 enzyme 3A4 (CYP3A4), and
Eintrag öffnenCalquence · 4.5 · Acalabrutinib may increase exposure to co-administered BCRP substrates (e.g., methotrexate) by inhibition of i
Eintrag öffnenCalquence · 4.5 · Acalabrutinib may increase exposure to co-administered BCRP substrates (e.g., methotrexate) by inhibition of i
Eintrag öffnenCalquence · 4.5 · Acalabrutinib solubility decreases with increasing pH. Co-administration of acalabrutinib with an antacid (1 g
Eintrag öffnenCalquence · 4.5 · Active substances that may decrease acalabrutinib plasma concentrations
Eintrag öffnenCalquence · 4.5 · Active substances that may decrease acalabrutinib plasma concentrations
Eintrag öffnenCalquence · 4.5 · Active substances that may increase acalabrutinib plasma concentrations
Eintrag öffnenCalquence · 4.5 · Active substances that may increase acalabrutinib plasma concentrations
Eintrag öffnenCalquence · 4.5 · Based on in vitro data, it cannot be excluded that acalabrutinib is an inhibitor of CYP3A4 at the intestinal l
Eintrag öffnenCalquence · 4.5 · Based on in vitro data, it cannot be excluded that acalabrutinib is an inhibitor of CYP3A4 at the intestinal l
Eintrag öffnenCalquence · 4.5 · Co--administration of a strong CYP3A inducer (600 mg rifampicin once daily for 9 days) decreased acalabrutinib
Eintrag öffnenCalquence · 4.5 · Co-administration of a strong CYP3A inducer (600 mg rifampicin once daily for 9 days) decreased acalabrutinib
Eintrag öffnenCalquence · 4.5 · Effect of acalabrutinib on CYP1A2 substrates
Eintrag öffnenCalquence · 4.5 · Effect of acalabrutinib on CYP1A2 substrates
Eintrag öffnenCalquence · 4.5 · Effects of acalabrutinib and its active metabolite, ACP-5862, on medicinal product transport systems
Eintrag öffnenCalquence · 4.5 · Effects of acalabrutinib and its active metabolite, ACP-5862, on medicinal product transport systems
Eintrag öffnenCalquence · 4.5 · In vitro studies indicate that acalabrutinib induces CYP1A2. Co-administration of acalabrutinib with CYP1A2 su
Eintrag öffnenCalquence · 4.5 · In vitro studies indicate that acalabrutinib induces CYP1A2. Co-administration of acalabrutinib with CYP1A2 su
Eintrag öffnen